Abstract:Background and Aims: MicroRNA-21 (miR-21) is reported to be overexpressed and to contribute to proliferation, apoptosis and gemcitabine resistance in pancreatic ductal adenocarcinomas (PDACs). The aims of this study were to explore regulation of miR-21 expression by epigenetic change and its impact on chemoresistance and malignant properties of of pancreatic cancer. Materials and methods: We retrospectively collected 41 cases of advanced pancreatic cancer patients who were sensitive or resistant to gemcitabine and assessed levels of serum circulating miR-21 for correlation with cytotoxic activity. Histone acetylation in the miR-21 promoter was also studied in gemcitabine-sensitive and gemcitabine-resistant PDAC cells. Gemcitabine-resistant HPAC and PANC-1 cells were transfected with pre-miR-21 precursors (pre-miR-21) and antisense oligonucleotides (anti-miR-21), and were treated with TSA. Finally, invasion and metastasis assays were performed and alteration in mir-21, PTEN, AKT and pAKT level was evaluated in these cells. Results: Serum miR-21 levels were increased in gemcitabine-resistant PDAC patients compared with gemcitabine-sensitive subjects. The miR-21 levels were increased in 6 PDAC cells treated with gemcitabine significantly, associated with 50% inhibitory concentrations (IC(50)s). Histone acetylation levels at miR-21 promoter were increased in PDAC cells after treatment with gemcitabine. Enhanced invasion and metastasis, increased miR-21 expression, decreased PTEN, elevated pAKT level were demonstrated in gemcitabine-resistant HPAC and PANC-1 cells. Pre-miR-21 transfection or TSA treatment further increased invasion and metastasis ability, decreased PTEN, and elevated pAKT levels in these two lines. In contrast, anti-miR-21 transfection could reverse invasion and metastasis, and PTEN and pAKT expressions induced by gemcitabine. Conclusions: MiR-21 upregulation induced by histone acetylation in the promoter zone is associated with chemoresistance to gemcitabine and enhanced malignant potential in pancreatic cancer cells.

Mir-33A Suppresses the Nuclear Translocation of Β-Catenin to Enhance Gemcitabine Sensitivity in Human Pancreatic Cancer Cells

MicroRNA-33a-mediated Downregulation of Pim-3 Kinase Expression Renders Human Pancreatic Cancer Cells Sensitivity to Gemcitabine

Down regulation of miR-33a is involved in gemcitabine chemoresistance in human pancreatic cancer

Downregulation of Mir-301A-3p Sensitizes Pancreatic Cancer Cells to Gemcitabine Treatment Via PTEN.

Mir-19B-3p Promotes Human Pancreatic Cancer Capan-2 Cells Proliferation by Targeting Phosphatase and Tension Homolog

MiR-199 Reverses the Resistance to Gemcitabine in Pancreatic Cancer by Suppressing Stemness Through Regulating the Epithelial–Mesenchymal Transition

MicroRNA-410-3p Attenuates Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma by Inhibiting HMGB1-mediated Autophagy

Gemcitabine Enhances OSI-027 Cytotoxicity by Upregulation of Mir-663A in Pancreatic Ductal Adenocarcinoma Cells

MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.

Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells Through Modulation of Mir-200 and Mir-21 Expression by Curcumin or Its Analogue CDF.

miR-17-5p Inhibitor Enhances Chemosensitivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer Cells

miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.

Mechanisms of spermidine/spermine N1-acetyltransferase 2 in the chemoresistance of pancreatic cancer to gemcitabine

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma

Down-Regulation Of Microrna-20a In Gemcitabine-Resistant Pancreatic Cancer In In Vitro Microrna Integrative Analysis

MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells

Mir-21 Upregulation Induced by Promoter Zone Histone Acetylation is Associated with Chemoresistance to Gemcitabine and Enhanced Malignancy of Pancreatic Cancer Cells

Mir-3656 Expression Enhances the Chemosensitivity of Pancreatic Cancer to Gemcitabine Through Modulation of the RHOF/EMT Axis.

PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer

MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX